Question

I am a breastfeeding mother and i want to know if it is safe to use UNII-5J49Q6B70F? Is UNII-5J49Q6B70F safe for nursing mother and child? Does UNII-5J49Q6B70F extracts into breast milk? Does UNII-5J49Q6B70F has any long term or short term side effects on infants? Can UNII-5J49Q6B70F influence milk supply or can UNII-5J49Q6B70F decrease milk supply in lactating mothers?

UNII-5J49Q6B70F lactation summary

UNII-5J49Q6B70F is dangerous in breastfeeding
  • DrLact safety Score for UNII-5J49Q6B70F is 7 out of 8 which is considered Dangerous as per our analyses.
  • A safety Score of 7 indicates that usage of UNII-5J49Q6B70F may cause toxic or severe side effects in breastfed baby.
  • Our study of different scientific research indicates that UNII-5J49Q6B70F may cause moderate to high side effects or may affect milk supply in lactating mother.
  • Our suggestion is to use safer alternate options rather than using UNII-5J49Q6B70F .
  • Usage of UNII-5J49Q6B70F is in contradiction to breastfeeding hence if it is must to use UNII-5J49Q6B70F and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About UNII-5J49Q6B70F usage in lactation

Drug is cleared from the body in 5 elimination half-lives. Return to breastfeeding is likely safe after 35 days of pumping-discarding of the milk.

Answer by DrLact: About UNII-5J49Q6B70F usage in lactation

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.[1] It is probably impractical to resume breastfeeding after UNII-5J49Q6B70F therapy because of the drug's long half-life. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2]

UNII-5J49Q6B70F Side Effects in Breastfeeding

In a 4-month-old, neutropenia was probably caused by cyclophosphamide in a mother 9 days after the last of 6 weekly doses of 800 mg cyclophosphamide intravenously, 2 mg UNII-5J49Q6B70F intravenously and daily doses of 30 mg of prednisolone orally. Neutropenia persisted at least 12 days and was accompanied by a brief episode of diarrhea.[3] The contribution of UNII-5J49Q6B70F to the neutropenia cannot be determined.

Alternate Drugs

Thioguanine(Dangerous)
Cladribine(Dangerous)
Erlotinib(Unsafe)
Letrozole(Dangerous)
Dasatinib(Unsafe)
Exemestane(Dangerous)
Vincristine(Dangerous)
Nilotinib(Unsafe)
Tamoxifen(Dangerous)
Mitoxantrone(Dangerous)
Dactinomycin(Dangerous)
Ipilimumab(Unsafe)
Cetuximab(Unsafe)
Carboplatin(Dangerous)
Hydroxyurea(Low Risk)
Paclitaxel(Dangerous)
Etoposide(Dangerous)
Fluorouracil(Dangerous)
Nivolumab(Unsafe)
Doxorubicin(Dangerous)
Gemcitabine(Dangerous)
Alemtuzumab(Low Risk)
Vinblastine(Dangerous)
Cyclophosphamide(Dangerous)
Rituximab(Low Risk)
Bleomycin(Dangerous)
Docetaxel(Dangerous)
Cisplatin(Unsafe)
Bevacizumab(Low Risk)
Vinorelbine(Dangerous)
Busulfan(Dangerous)
Pazopanib(Unsafe)
Dacarbazine(Dangerous)
Trastuzumab(Unsafe)
Imatinib(Unsafe)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.